CClinicalTrials.gg
CompletedNCT05620979Updated Nov 21, 2024

Financial Navigation Study Among Young Adult Blood Cancer Survivors

An interventional study of Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation. in Survivorship, Cancer and Financial Stress, sponsored by Tufts Medical Center. Completed at 5 sites in United States. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Tufts Medical Center · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Feb 2022, registered Oct 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
All
01

Study summary

Young adult cancer survivors (18-39y) are at increased risk of financial distress. This study seeks to better understand the financial challenges experienced by these individuals via quantitative serial assessments, study-based financial navigator encounters and an end of study qualitative interview.

Read the detailed description

This fully remote, multi-site study will evaluate the role of financial navigators in relieving financial distress in young adults (18-39y) who have completed treatment for blood cancer at least three years ago. Serial Assessments at study entry, 3-months, and 6-months measure financial distress measured using the study's primary outcome measure the Personal Financial Wellness Scale™ (PFW) (see below), hypothesized effect modifiers (emotional distress, self-efficacy, cognitive functioning), as well as care seeking, household finances and insurance characteristics. Randomization will occur following completion of baseline measures (see below for description of study arms). In addition to a formal evaluation of the intervention at 3- and 6-months, an optional interview will occur following the 6-month assessment/navigation intervention period to gain further insight from participants about the acceptability of the intervention. For ethical considerations related to the topic of study, all participants will be provided with the Leukemia \& Lymphoma Society's information specialist hotline.

02

Conditions studied

  • Survivorship
  • Cancer
  • Financial Stress
03

In context

Hematologic Neoplasms

1,464 studies on the registry are indexed under Hematologic Neoplasms; 433 are open to participants now.

This study's enrollment of 130 is above the median of 45 across 1,068 interventional studies indexed under Hematologic Neoplasms.

Browse Hematologic Neoplasms studies →

Lead sponsor

Tufts Medical Center is the lead sponsor of 194 studies on the registry; 28 are open to participants now.

Of its 30 completed or terminated interventional studies of FDA-regulated products, 16 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Previous diagnosis and treatment of blood cancer (leukemia, lymphoma, myeloma, myelodysplastic syndrome, or myeloproliferative neoplasm)
  2. Current age between 18-39 years old
  3. Blood cancer diagnosis during childhood (0-17 years of age) or young adulthood (18-36 years of age)
  4. At least three years post blood cancer diagnosis
  5. Off treatment for blood cancer or on a long-term regimen with an oral anti-cancer medication with stable disease
  6. Off treatment for a second cancer (non-blood cancer) or on a stable long-term regimen, such as hormone therapy or hormone replacement therapy
  7. Primary residence in United States
  8. Able to understand and read the English language

Exclusion criteria

Exclusion Criteria:

  • On parent or guardian's insurance
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Active comparator
    Active Navigation

    Active navigation with the study-based financial navigator scheduling four check-in meetings throughout the study with the participant. All participants will complete an assessment at baseline, 3 months and 6 months and be invited to participate in an optional interview after the 6-month assessment.

    Behavioral: Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.

  • Active comparator
    Ad Hoc Navigation

    Ad hoc navigation in which participant is provided study-based financial navigator to contact as needed. All participants will complete an assessment at baseline, 3 months and 6 months and be invited to participate in an optional interview after the 6-month assessment.

    Behavioral: Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.

  • Active comparator
    No study-based Navigation

    No access to a study-based financial navigator, but access to a national hotline through the Leukemia \& Lymphoma Society. All participants will complete an assessment at baseline, 3 months and 6 months and be invited to participate in an optional interview after the 6-month assessment.

    Behavioral: Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.

Interventions

  • BehavioralProviding financial navigation via active navigation, ad hoc navigation or no study-based navigation.

    Providing financial navigation to blood cancer survivors.

06

What researchers measure

Primary outcomes

  1. Personal Financial Wellness Scale (PFW)

    To evaluate the change in financial distress associated with randomization group assignment from baseline to 6-month follow up as measured by the 8-item Personal Financial Wellness Scale (PFW). The PFW scores range from 1-10 where lower scores indicate greater financial distress.

    Time frame: 6 months

Secondary outcomes

  1. Health-Related Quality of Life (HrQoL) Measures

    As part of Aim 1, we will explore whether changes in financial distress (baseline to 6-months) are moderated by emotional distress, self-efficacy, and cognitive functioning, as measured by Patient-Reported Measurement Information System (PROMIS) 4-item short forms for emotions distress (depression and anxiety) and self-efficacy, as well as the 4-item cognitive functioning scale from the Quality of Life in Neurological Disorders (Neuro-Qol) battery. For each of these short forms, high scores connote better functioning.

    Time frame: 6 months

07

Study locations

5 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • University of Southern California (USC Norris Comprehensive Cancer Center & LA County Hospital)
    Los Angeles, California 90033, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Bon Secours Mercy Health System
    Greenville, South Carolina 29607, United States
  • MD Anderson
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05620979
Lead sponsor
Tufts Medical Center
Collaborators
The Leukemia and Lymphoma Society
Responsible party
Sponsor
First posted
Nov 17, 2022
Start date
Feb 14, 2022
Primary completion
Nov 6, 2023
Completion
Nov 23, 2023
Last update
Nov 21, 2024

Study contacts

Susan K Parsons, MD, MRP
principal investigator · Tufts Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion